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ABSTRACT

◥

Introduction: We retrospectively assessed prognostic value of
circulating cell-free DNA (cfDNA) using data from the phase III
ALEX study in treatment-na€ve, advanced ALKþ non–small cell
lung cancer (NSCLC).
Methods: Patients were randomized to receive twice-daily
alectinib 600 mg (n ¼ 152) or crizotinib 250 mg (n ¼ 151).
cfDNA was quantiﬁed from baseline plasma samples, with
patients stratiﬁed into ≤median and >median cfDNA biomarker-evaluable populations (BEP). Effect of cfDNA concentration
on outcomes was analyzed using a Cox regression model with
treatment group as covariate, and in multivariate analyses.
Results: Median cfDNA concentration in the BEP was
11.53 ng/mL (n ¼ 276). A positive correlation was found between
cfDNA concentration and number of lesions, organ lesion sites,
and tumor size (sum of longest diameter; all P < 0.0001). In both

Introduction
Patients whose tumors harbor a rearrangement of the anaplastic
lymphoma kinase gene (ALKþ) account for approximately 5% of all
patients with non–small cell lung cancer (NSCLC; refs. 1, 2). Tumor
biopsy remains the gold standard for accurate diagnosis and prognosis
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treatment arms, patients in the >median BEP were more likely
to experience disease progression than the ≤median BEP
[alectinib adjusted HR ¼ 2.04; 95% conﬁdence interval (CI),
1.07–3.89; P ¼ 0.0305 and crizotinib adjusted HR ¼ 1.83; 95% CI,
1.11–3.00, P ¼ 0.0169]. Median progression-free survival was
longer with alectinib than crizotinib in both ≤median and
>median BEPs (P < 0.0001). Overall survival data remain immature; survival probability was lower in the >median versus
≤median BEP in both treatment arms (alectinib HR ¼ 2.52;
95% CI, 1.08–5.88; P ¼ 0.0333 and crizotinib HR ¼ 2.63; 95% CI,
1.27–5.47; P ¼ 0.0096).
Conclusions: These data suggest that plasma cfDNA concentration may have prognostic value in advanced ALKþ NSCLC.
Prospectively designed studies are warranted to investigate this
ﬁnding.
of NSCLC, but it is associated with inherent drawbacks. These include
potential problems with the quantity and quality of the tissue obtained,
the invasive nature of the procedure, and selection bias resulting from
tumor heterogeneity (3).
Plasma-based testing for molecular genomics has the potential to
overcome some of the limitations of tissue sampling, and thereby
enable clinicians to offer more effective personalized therapies (3, 4).
Furthermore, the clinical utility of circulating cell-free DNA (cfDNA)
in serum and plasma has been an area of active research in many
medical disciplines. cfDNA is believed to originate from multiple
sources, including white blood cells, apoptotic/necrotic tumor cells,
living tumor cells, and circulating tumor cells, and is therefore present
in both healthy and diseased individuals (5, 6). Increased levels of
cfDNA have been observed in patients with cancer and may harbor the
genomic alterations present in the original tumor (7).
Previous research has indicated that increased baseline cfDNA
concentration is linked with poor prognosis in NSCLC (8–10). Studies
have also shown that cfDNA can act as a potential molecular prognostic marker for NSCLC; patients with NSCLC and lymph node
metastasis or distant metastasis had higher cfDNA levels, associated
with a shorter overall survival (OS; refs. 11–13). However, the correlation of cfDNA with outcomes after treatment with ALK inhibitors
has not yet been characterized. Other biomarkers have also shown
prognostic value in patients with ALKþ NSCLC, such as the presence
of a TP53 comutation which has been associated with poorer outcomes
regardless of the systemic therapy received (14, 15).
The phase III, global, randomized ALEX study (NCT02075840)
compared two ALK inhibitors, alectinib and crizotinib, in patients with
treatment-na€ve advanced ALKþ NSCLC. Alectinib demonstrated
superior efﬁcacy to crizotinib, with a favorable safety proﬁle, at the
primary data cutoff (February 9, 2017; ref. 16) and in three subsequent
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Translational Relevance
Studies have shown that circulating cell-free DNA (cfDNA) may
act as a molecular prognostic marker for non–small cell lung cancer
(NSCLC), with higher cfDNA levels associated with poor prognosis. The correlation of cfDNA with outcomes after treatment
with ALK inhibitors has not yet been characterized. This retrospective analysis assessed the prognostic potential of cfDNA using
data from the phase III ALEX study comparing alectinib and
crizotinib in treatment-na€ve advanced ALKþ NSCLC. A positive
correlation was found between cfDNA concentration and number
of lesions, organ lesion sites, and tumor size. Patients with ≤median
cfDNA had a lower risk of disease progression than those with
>median cfDNA, along with a higher probability of survival.
Alectinib consistently improved outcomes versus crizotinib,
regardless of baseline cfDNA concentration, and reduced the risk
of tumor progression by more than 50%. These ﬁndings suggest
that plasma cfDNA concentration may have prognostic value for
the treatment of advanced ALKþ NSCLC.

analyses after longer-term follow up; after an additional 10 months
(17), 22 months, and 32 months (18). Here, we examine the prognostic
potential of total baseline quantitative cfDNA using data from the
ALEX study.

Materials and Methods
Study design
In the ALEX study, 303 patients were randomized 1:1 to receive
twice-daily alectinib 600 mg or crizotinib 250 mg until disease
progression, toxicity, withdrawal, or death. Full study details have
been described previously (16). Key eligibility criteria included
untreated advanced ALKþ NSCLC, conﬁrmed centrally by IHC
(VENTANA ALK D5F3), and an Eastern Cooperative Oncology
Group performance status of 0 to 2. Patients with asymptomatic
central nervous system (CNS) metastases were also permitted.
The ALEX study protocol was approved by the institutional review
board or ethics committee at each participating center, and the study
was conducted in accordance with the principles of the Declaration of
Helsinki, Good Clinical Practice Guidelines, and local laws. Written
informed consent was obtained from all patients before enrolment.
The data presented in this manuscript are taken from the November
30, 2018 data cutoff, after a median follow-up of 37.8 months with
alectinib and 23.0 months with crizotinib; and from the November 29,
2019 data cutoff, after a median follow-up of 48.2 months with
alectinib and 23.3 months with crizotinib.
Study assessments
Two 5-mL blood samples were taken at baseline from all randomized patients for retrospective pharmacogenomic research. Blood was
drawn into K2-EDTA blood collection tubes and centrifuged immediately at 1,500  g for 10 minutes. The plasma layer was carefully
transferred into a fresh tube and centrifuged again at 3,000  g for 10
minutes. The plasma samples were then transferred into two storage
tubes (plain cap transfer tubes) and stored immediately at 20 C or
70 C. Samples were shipped daily to the central laboratory for longterm storage. All plasma samples were analyzed using a hybrid
capture-based NGS assay (FoundationACT, Foundation Medicine
Inc.). cfDNA, deﬁned as any volume of DNA detected in plasma, was
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extracted from baseline plasma samples and the concentration was
determined in nanograms per milliliter using the D1000 ScreenTape
assay on the 4200 TapeStation (Agilent Technologies; ref. 19).
Patients were stratiﬁed into ≤median cfDNA and >median cfDNA
biomarker-evaluable populations (BEP). Plasma samples were also
evaluated for the presence of a TP53 mutation, which is associated
with reduced OS in ALKþ NSCLC (20). Circulating tumor DNA
was assessed using plasma samples and patients were classiﬁed as
circulating tumor DNA-positive when any somatic (known or likely
status) alteration (short variants, rearrangement, or copy number)
was detected, or otherwise as circulating tumor DNA-negative.
Endpoints
Endpoints of the ALEX study, including progression-free survival
(PFS), objective response rate (ORR), duration of response (DoR), and
OS were determined by investigator assessment. The objective of this
exploratory analysis was to examine the prognostic value of cfDNA on
PFS, ORR, DoR, and OS.
Statistical analyses
KaplanMeier methodology was used to assess the association
between cfDNA concentration (stratiﬁed by ≤median and >median
BEP) and PFS, DoR, and OS. The association between cfDNA
concentration and PFS, DoR, and OS was analyzed using a Cox
regression model with treatment group as unique covariate, in addition
to separate multivariate analyses adjusting for the presence of
a TP53 mutation; measurable/nonmeasurable CNS lesions at baseline;
baseline tumor size [measured as the baseline sum of longest diameter
(SLD)], number of organ sites, and number of liver lesions.
Associations between PFS and TP53 mutation status and ALK rearrangement status according to cfDNA concentration were assessed
using an unadjusted, unstratiﬁed Cox regression model. The association between cfDNA concentration and ORR was analyzed using a
binomial logistic regression model. All regression analyses were
performed considering cfDNA as both a categorical and continuous
(log2-transformed) variable. Associations between cfDNA concentration and outcome were analyzed at the time when data for the
study endpoints were last reported: at the November 30, 2018 data
cutoff for PFS, DoR, and ORR, and at the November 29, 2019 data
cutoff for OS.
Data availability statement
Qualiﬁed researchers may request access to individual patientlevel data through the clinical study data request platform (https://
vivli.org/). Further details on Roche’s criteria for eligible studies
are available here (https://vivli.org/members/ourmembers/). For
further details on Roche’s Global Policy on the Sharing of Clinical
Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/
who_we_are_how_we_work/clinical_trials/our_commitment_to_data_
sharing.htm).

Results
Patients
Baseline plasma samples were available for 276 patients; the
median cfDNA concentration was 11.53 ng/mL (range 1.6–64.5)
for all patients, 11.73 ng/mL in the alectinib treatment arm,
and 10.85 ng/mL in the crizotinib treatment arm. Twenty-seven
samples were unavailable for analysis. Of 222 (80%) patients with
results from the FoundationACT assay, 135 patients (61%) had an
EML4-ALK rearrangement detected, 10 patients (5%) had an ALK
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Table 1. Baseline characteristics of the ≤median cfDNA and >median cfDNA BEPs according to treatment group.
Crizotinib

Median age (range), years
Aged <65 years, n (%)
Smoking status, n (%)
Active smoker
Nonsmoker
ECOG PS, n (%)
0 or 1
2
CNS lesions,a n (%)
TP53-mutant, n/N (%)

Alectinib

≤median cfDNA
(n ¼ 72)

>median cfDNA
(n ¼ 67)

≤median cfDNA
(n ¼ 66)

>median cfDNA
(n ¼ 71)

54 (18–91)
55 (76.4)

54 (28–81)
51 (76.1)

57.5 (28–88)
46 (69.7)

58 (28–81)
56 (78.9)

2 (2.8)
48 (66.7)

1 (1.5)
43 (64.2)

5 (7.6)
35 (53.0)

5 (7.0)
48 (67.6)

70 (97.2)
2 (2.8)
23 (31.9)
11/51 (21.6)

61 (91.0)
6 (9.0)
28 (41.8)
21/64 (32.8)

66 (100.0)
0
20 (30.3)
10/40 (25.0)

61 (85.9)
10 (14.1)
34 (47.9)
30/67 (44.8)

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.
a
Measurable and nonmeasurable CNS lesions.

rearrangement with a non-EML4 fusion partner, and 77 patients
(35%) had no ALK rearrangement detected.
The BEP was generally representative of the overall ALEX study
population; baseline characteristics were balanced between the treatment arms within the BEP (crizotinib n ¼ 139, alectinib n ¼ 137).
There were more active smokers in the alectinib arm than in the
crizotinib arm in both the >median cfDNA BEP (7.0% versus 1.5%,
respectively) and the ≤median cfDNA BEP (7.6% versus 2.8%, respectively). In the >median cfDNA BEP, the alectinib arm contained
slightly more patients with CNS lesions compared with the crizotinib
arm (47.9% versus 41.8%, respectively) and more patients with TP53
mutations (44.8% versus 32.8%, respectively; Table 1). These characteristics were generally more balanced in the ≤median cfDNA BEP.
Biomarker concentration by relevant drug and patient factors
Alectinib exposure (Ctrough) was not substantially different between
the ≤median cfDNA and >median cfDNA BEPs, and there was a trend
for wider distribution of a slightly lower exposure in the >median
cfDNA BEP (Supplementary Fig. S1). More than 95% of patients
achieved alectinib exposures sufﬁcient to maximize PFS, based on
previous exposure-response analyses (21, 22). There was a signiﬁcant
difference in median cfDNA concentration in patients with no detectable ALK rearrangement in cfDNA (10.91 ng/mL; n ¼ 77) and a
detectable ALK rearrangement in cfDNA (16.37 ng/mL; n ¼ 145;
P < 0.0001).
A trend for slightly higher cfDNA concentration was observed with
the presence of measurable/nonmeasurable CNS lesions and TP53
mutations. Median cfDNA concentration was 12.57 ng/mL in patients
with measurable CNS lesions and 10.68 ng/mL in patients without
(P < 0.05; Fig. 1A), and 17.98 ng/mL in patients with TP53 mutations
and 12.10 ng/mL in patients without (P < 0.001; Fig. 1B). A trend
towards higher median cfDNA concentration was seen in patients with
liver lesions (Fig. 1C; Supplementary Table S1).
A positive correlation was found between cfDNA concentration and
the number of measurable/nonmeasurable lesions (Spearman correlation 0.30; P < 0.0001; Fig. 2A); the number of organ lesion sites
(Spearman correlation 0.38; P < 0.0001; Fig. 2B); and tumor size (SLD)
by investigator (Spearman correlation 0.38; P < 0.0001; Fig. 2C).
Efﬁcacy
Investigator-assessed median PFS was longer for alectinib than for
crizotinib in both the ≤median and >median cfDNA BEPs (Fig. 3A).
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In the ≤median cfDNA BEP, median PFS was not estimable (NE;
95% CI, 34.9–NE) in the alectinib arm and 14.8 months (95% CI,
12.7–25.6) in the crizotinib arm (HR ¼ 0.38; 95% CI, 0.23–0.61; P <
0.0001). Comparatively, in the >median cfDNA BEP, median PFS
was 14.8 months (95% CI, 10.9–40.4) in the alectinib arm and
8.6 months (95% CI, 7.2–10.8) in the crizotinib arm (HR ¼ 0.43;
95% CI, 0.29–0.65; P < 0.0001). In the adjusted analysis, the
likelihood of experiencing a progression event was lower for
patients in the >median cfDNA BEP of the alectinib arm than
those in the ≤median cfDNA BEP of the crizotinib arm (HR ¼ 0.46;
95% CI, 0.27–0.77; P < 0.05). The biomarker effect (>median cfDNA
versus ≤median cfDNA BEP) in the unadjusted analysis in the
alectinib arm (HR ¼ 1.94; 95% CI, 1.20–3.15; P ¼ 0.0071) and in the
crizotinib arm (HR ¼ 2.10; 95% CI, 1.44–3.07; P ¼ 0.0001) was
similar to the effect observed in the adjusted analysis in the alectinib
(HR ¼ 2.04; 95% CI, 1.07–3.89; P ¼ 0.0305) and crizotinib arms
(HR ¼ 1.83; 95% CI, 1.11–3.00; P ¼ 0.0169; Supplementary
Table S2). Similar results were observed when cfDNA concentration
was analyzed as a continuous value (Supplementary Table S2).
Multivariate analysis of covariate effects on PFS by investigator
are summarized in Fig. 4. cfDNA levels remain signiﬁcantly associated with PFS after adjusting for variables representative of tumor
burden. The higher HR for PFS in the >median cfDNA BEP
compared with the ≤median cfDNA BEP was consistent irrespective
of the cfDNA cut-off value used (Supplementary Fig. S2). Additionally, in a quartile analysis of cfDNA concentration, the greatest
PFS probability in both treatment arms occurred in patients in the
0% to 25% quartile of cfDNA concentration, followed by patients
in the 25% to 50%, 50% to 75%, and 75% to 100% quartiles,
respectively (Supplementary Fig. S3).
When evaluating plasma circulating tumor DNA, we observed a
trend for higher baseline cfDNA concentration in patients who were
circulating tumor DNA-positive (containing a known or likely alteration) and a trend for lower baseline cfDNA concentration in patients
who were circulating tumor DNA-negative (Supplementary Fig. S4).
With alectinib, median PFS in the circulating tumor DNA-positive
subgroup was 22.4 months (95% CI, 14.6–NE) compared with NE
(95% CI, NE–NE) in the circulating tumor DNA-negative subgroup
(HR ¼ 2.72; 95% CI, 1.16–6.35; P ¼ 0.0210 unadjusted
analysis; Fig. 3B). With crizotinib, median PFS in the circulating
tumor DNA-positive subgroup was 8.8 months (95% CI, 7.3–10.8)
compared with 16.6 months (95% CI, 10.8–27.6) in the circulating

Clin Cancer Res; 2022

OF3

Dziadziuszko et al.

B

500

500

300

300
cfDNA concentration (ng/mL)

cfDNA concentration (ng/mL)

A

100
50
30
10
5
3
1

Figure 1.
Correlation of normalized cfDNA
concentration with the presence of
A, Measurable/nonmeasurable CNS
lesions, B, TP53 mutation status, and
C, by organ lesion site (investigator
assessment). Central lines represent
median values, boxes represent interquartile ranges (IQR) and the top and
bottom whiskers extend to the largest
and smallest value, respectively, no
further than 1.5 times the IQR.
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tumor DNA-negative subgroup (HR ¼ 2.03; 95% CI, 1.22–3.37;
P ¼ 0.0066 unadjusted analysis). A nonsigniﬁcant trend for
the biomarker effect was also observed in both treatment groups in
the adjusted analyses (alectinib HR ¼ 1.95; 95% CI, 0.78–4.83;
P ¼ 0.1506; and crizotinib HR ¼ 1.52; 95% CI, 0.88–2.63; P ¼ 0.1323).
When the association between TP53 comutation status and the
biomarker effect of cfDNA concentration on PFS was analyzed, a
longer median PFS was seen in the ≤median cfDNA BEP than the
>median cfDNA BEP in both the alectinib and crizotinib arms,
irrespective of TP53 mutation status (Supplementary Fig. S5). When
cfDNA concentration was considered as a continuous variable, a
similar biomarker effect (longer median PFS with lower cfDNA
concentration) was observed, which was signiﬁcant in both treatment
arms (Supplementary Table S3). A similar trend was seen when the
association between detection of an ALK rearrangement in cfDNA and
the biomarker effect of cfDNA concentration on PFS was analyzed
(Supplementary Fig. S6); a longer median PFS was seen in the ≤median
cfDNA BEP compared with the >median cfDNA BEP in both the
alectinib and crizotinib arms, irrespective of the detection of an ALK
rearrangement. When cfDNA concentration was considered as a
continuous variable, the biomarker effect on PFS was signiﬁcant across
all comparisons in both treatment groups (Supplementary Table S4).
ORR by investigator was numerically higher in the ≤median cfDNA
BEP compared with the >median cfDNA BEP in both treatment arms

OF4 Clin Cancer Res; 2022

(Table 2). In the ≤median cfDNA BEP, ORR was 88.7% in the alectinib
arm and 80.3% in the crizotinib arm; in the >median cfDNA BEP, ORR
was 86.6% in the alectinib arm and 72.3% in the crizotinib arm. No
signiﬁcant difference was seen between the ≤median cfDNA and
>median cfDNA BEPs in either the alectinib (P ¼ 0.9191) or crizotinib
(P ¼ 0.3720) arms. Similar results for ORR were observed when cfDNA
was analyzed as continuous value (Supplementary Table S5). Median
DoR by investigator in the ≤median cfDNA BEP was NE in the
alectinib arm (95% CI, NE–NE) compared with 18.4 months in the
crizotinib arm (95% CI, 11.3–25.8); in the >median cfDNA BEP,
median DoR was 29.6 months (95% CI, 12.9–NE) in the alectinib arm
compared with 7.0 months (95% CI, 5.5–11.1) in the crizotinib arm
(Fig. 3C).
The 5-year OS data from ALEX (data cutoff: November 29, 2019)
used for this analysis remain immature. In the ≤median cfDNA
BEP, median OS was NE (95% CI, NE–NE) in both treatment
arms. Comparatively, in the >median cfDNA BEP, median OS
was NE (95% CI, 27.7–NE) in the alectinib arm and 21.4 months
(95% CI, 16.9–47.7) in the crizotinib arm (Fig. 3D). Survival
probability was lower in the >median cfDNA BEP compared with
the ≤median cfDNA BEP, in both the alectinib arm (HR ¼ 2.58; 95%
CI, 1.37–4.86; P ¼ 0.0033) and the crizotinib arm (HR ¼ 3.53; 95% CI,
1.99–6.28; P < 0.0001). This was consistent with the ﬁndings of
the multivariate analysis in both the alectinib arm (HR ¼ 2.52; 95%
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Figure 2.
Correlation of normalized cfDNA concentration and A, number of lesions, B, number of organ sites, and C, tumor size (investigator assessment). Blue lines represent
hazard functions as determined by Cox multivariate analyses. Grey shaded areas represent 95% CIs. ctDNA, circulating tumor DNA.

CI, 1.08–5.88; P ¼ 0.0333) and the crizotinib arm (HR ¼ 2.63; 95% CI,
1.27–5.47; P ¼ 0.0096).

Discussion
In this retrospective analysis of the ALEX study, the number of
lesions, organ lesion sites, and tumor size positively correlated with
cfDNA concentration; patients with ≤median cfDNA had a lower risk
of disease progression than those with >median cfDNA, along with a
higher probability of survival. These data suggest that cfDNA concentration could potentially be used as a prognostic indicator and
surrogate marker for tumor and overall disease burden, although it
should be noted that ALK rearrangement was not detected in cfDNA in
35% of patients in this analysis. Reasons for these false negative results
are currently unclear and do not appear to correlate with patient
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demographic or disease characteristics, but they may be related to the
lower concentrations of cfDNA in patient samples where ALK rearrangement was not detected in cfDNA.
Alectinib consistently improved PFS, ORR, and DoR versus crizotinib, regardless of BEP subgroup, and reduced the risk of tumor
progression by more than 50%. Additional analyses showed that
patients in the “poor prognosis” group (>median cfDNA) treated
with alectinib had either a similar median PFS (unadjusted analysis)
or a longer median PFS (adjusted analysis) than patients in the
“good prognosis” group (≤median cfDNA) treated with crizotinib.
These data support alectinib as a preferred ﬁrst-line treatment option
for advanced ALKþ NSCLC (23, 24). Compared with results from the
intent-to-treat (ITT) population at the same data cutoff, the PFS of
patients in the >median BEP was lower in both treatment arms (18).
Although OS data remain immature, OS was NE for the alectinib
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Figure 3.
Kaplan–Meier analysis of A, PFS by median cfDNA BEP, B, PFS by circulating tumor DNA status, C, DoR by median cfDNA BEP, and D, OS by median cfDNA BEP. PFS
and DoR were investigator-assessed.

treatment arm in both arms of the BEP and the ITT, and the crizotinib
arm of the >median BEP had a numerically lower OS than the ITT (18).
At the present stage, the diagnosis and treatment of cancer is greatly
dependent on molecular detection of tumor-derived genes, but tumor
tissue biopsies are limited by their invasiveness, selection bias for
heterogeneity, and inability to monitor the ongoing evolution of a
tumor. Although this analysis focuses on the prognostic value of
cfDNA, from a diagnostic perspective, cfDNA can be extracted from
blood and measured, and so may overcome some of the limitations
seen with using tissue samples. However, the practical application of
the use of cfDNA data in a clinical setting is still not widely understood.
One step towards improving our understanding of the clinical utility
of cfDNA will be to assess whether temporal changes in cfDNA levels
during the course of ALK inhibitor monotherapy can be correlated
with radiologic progression and other key trial endpoints, in order to
monitor the progression of ALKþ NSCLC. Data from other studies
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have suggested that changes in cfDNA concentration during the course
of lung cancer treatment may not correlate well with radiologic CT
responses (8, 9). In the present analysis, patients with ≤median cfDNA
at baseline had a numerically higher ORR than patients with >median
cfDNA at baseline, which was more pronounced in the crizotinib arm.
This is in line with the concept that patients with higher cfDNA levels
may have a higher tumor burden and belong to a worse prognostic
patient group. We also noted a slight trend for higher cfDNA concentrations in patients with CNS lesions, which may be a further
indicator of higher overall tumor burden.
Another consideration for understanding the potential clinical
value of cfDNA is the optimal cut-off threshold for quantiﬁcation.
The median value of 11.53 ng/mL was used in this study to stratify
patients into separate BEPs, but this cutoff may not be applicable to
other patient populations. Indeed, the cut-off thresholds of plasma
cfDNA varied widely in a meta-analysis investigating the association
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concentrations; as such, these biomarkers may not be independent.
When adjusting for other variables representing tumor burden, such as
measurable/nonmeasurable CNS lesions at baseline, tumor size (measured as the baseline sum of longest diameter), number of organ sites,
and number of liver lesions, the prognostic effect of cfDNA remains in
both arms indicating that cfDNA may be an independent prognostic
marker and not only a possible surrogate for tumor burden.
Although the prognostic value of TP53 comutation on treatment
outcomes has been previously reported, these are the ﬁrst data
correlating cfDNA concentration (alone or in the context of other
biomarkers) with treatment outcomes (8–10, 14, 15). Our ﬁndings
suggest that cfDNA may have the potential to identify patients that are
likely to have a worse prognosis and may derive less beneﬁt from ALK
inhibitor monotherapy. ALK inhibitors have greatly improved outcomes for patients with ALKþ NSCLC (17, 18, 28, 29). Identiﬁcation of
a patient subgroup with a poorer prognosis will be important to
develop treatment strategies to overcome the negative prognostic
effect by intensiﬁcation of treatment beyond ALK inhibitor monotherapy; for example, by combination with chemotherapy or immunologic therapy.
It is important to note that this was a retrospective analysis of data
emerging from a clinical study. ALEX was not designed or powered to
investigate the impact of cfDNA on efﬁcacy with ALK inhibitors. The
results of this work are considered exploratory and would need to be
validated in a prospectively designed study with balanced arms for
cfDNA values to conﬁrm observed effects.
In summary, the results of this analysis suggest that plasma cfDNA
concentration may have prognostic value in patients with advanced
ALKþ NSCLC. These exploratory ﬁndings warrant further investigation in prospectively designed studies.
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